SLV-154 Treatment of Metastatic Solid Tumors

Phase 1 Recruiting 70 enrolled Solve Therapeutics

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.

Timeline

Start: 2025-05-14
Primary completion: 2027-01
Completion: 2027-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SLV-154	Unknown	0.75 mg/kg	Intravenous
Subject	SLV-154	Unknown	1.5 mg/kg	Intravenous
Subject	SLV-154	Unknown	3 mg/kg	Intravenous
Subject	SLV-154	Unknown	5 mg/kg	Intravenous
Subject	SLV-154	Unknown	7.5 mg/kg	Intravenous
Subject	SLV-154	Unknown	10 mg/kg	Intravenous
Subject	SLV-154	Unknown	12.5 mg/kg	Intravenous
Subject	SLV-154	Unknown	15 mg/kg	Intravenous

SLV-154 Treatment of Metastatic Solid Tumors

Summary

Timeline

Drugs

Indications